CXCR4 and B-cell chronic lymphocytic leukemia: Accordingly, highly active B‐cell receptor signalling inhibitors, such as ibrutinib, lead to egress of CLL cells from the lymphoid compartments to a periphery in a mechanism that involves decrease of surface CXCR4 expression.8